3-<<<2-(2,2-dimethylhydrazino)-4-thiazolyl>methyl>thio>-N²-sulfamoylpropionamidine | 81814-03-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-<<<2-(2,2-dimethylhydrazino)-4-thiazolyl>methyl>thio>-N²-sulfamoylpropionamidine
• 英文别名: 3-[[2-(2,2-dimethylhydrazino)thiazol-4-yl]methylsulfanyl]-N'-sulfamoyl-propanamidine；3-[[2-(2,2-dimethylhydrazinyl)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide
• CAS: 81814-03-1
• 化学式: C₉H₁₈N₆O₂S₃
• 分子量: 338.479
• InChiKey: MWBWKVQOODCNCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  189
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  ethyl 3-<<<2-<2,2-dimethylhydrazino>-4-thiazolyl>methyl>thio>propionimidate 、 磺酰胺 以29%的产率得到
  参考文献：
  名称：

  YANAGISAWA, ISAO;HIRATA, YASUFUMI;ISHII, YOSHIO, J. MED. CHEM., 30,(1987) N 10, 1787-1793

  摘要：

  DOI：

文献信息

• Studies on histamine H2 receptor antagonists. 2. Synthesis and pharmacological activities of N-sulfamoyl and N-sulfonyl amidine derivatives
  作者：Isao Yanagisawa、Yasufumi Hirata、Yoshio Ishii

  DOI：10.1021/jm00393a018

  日期：1987.10

  tested in vitro for H2 antihistamine activity on guinea pig atrium. In addition, several selected compounds were assessed as inhibitors of gastric acid secretion induced by histamine in anesthetized dogs. Structure-activity relationship studies showed that those compounds containing 2-[(diaminomethylene)amino]thiazole exhibited potent H2-receptor antagonist activity. Introduction of alkyl or aralkyl groups

  已经制备了一系列的N-氨磺酰基和N-磺酰基am，并在体外测试了对豚鼠心房的H 2抗组胺活性。另外，评估了几种选择的化合物作为组胺在麻醉狗中诱导的胃酸分泌的抑制剂。结构活性关系研究表明，那些含有2-[（（二氨基亚甲基）氨基]噻唑的化合物表现出有效的H2受体拮抗剂活性。将烷基或芳烷基引入氨磺酰基部分的末端氮会降低生物活性。在两个测试中，氨磺酰基am的作用均比磺酰基am强。这些化合物中，3-[[[[[2-[（二氨基亚甲基）氨基] -4-噻唑基]甲基]硫代] -N2-氨磺酰基丙ion（2e，法莫替丁）在两种试验中均显示出极高的效力，并被选作抗溃疡药进行临床试验。法莫替丁的酸催化水解在室温下产生氨磺酰基酰胺6，而在高温下产生羧酸7。15N NMR光谱表明，溶液中的法莫替丁仅存在于衍生自idine和胍部分的几种可能的互变异构体之一中。法莫替丁的亚硝化反应在温和的条件下进行，证明发生在噻唑环的5位上。
• PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS OF DRUGS SUCH AS CARBAMAZEPINE, CELECOXIB, OLANZAPINE, ITRACONAZOLE, TOPIRAMATE, MODAFINIL, 5-FLUOROURACIL, HYDROCHLOROTHAZIDE, ACETAMINOPHEN, ASPIRIN, FLURBIPROFEN, PHENYTOIN AND IBUPROFEN
  申请人：Transform Pharmaceuticals, Inc.

  公开号：EP1631260A2

  公开（公告）日：2006-03-08
• [EN] PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS<br/>[FR] COMPOSITIONS PHARMACEUTIQUES A BASE D'UN CO-CRISTAL
  申请人：TRANSFORM PHARMACEUTICALS INC

  公开号：WO2004078163A2

  公开（公告）日：2004-09-16

  A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphinic acid, phosphonic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, 0-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.
• YANAGISAWA, ISAO;HIRATA, YASUFUMI;ISHII, YOSHIO, J. MED. CHEM., 30,(1987) N 10, 1787-1793
  作者：YANAGISAWA, ISAO、HIRATA, YASUFUMI、ISHII, YOSHIO

  DOI：——

  日期：——